Study Highlights**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**Bispecific antibodies (BsAbs) exert their cytotoxic effect by bridging effector T cells and target cells to form immunological ternary complexes (TC) driving the pharmacodynamics. Currently, there are no generalized mathematical models and no quasi‐equilibrium (QE) approximation characterizing the relationship between dose and TC formation, which is essential for successful discovery, development, and clinical translation. There is a lack of mathematical framework that can help scientists *a priori* choose an optimal dosing strategy.**WHAT QUESTION DID THIS STUDY ADDRESS?**How to (i) develop the general target‐mediated drug disposition model for BsAb, (ii) construct the QE approximation, (iii) characterize the model dynamics, and (iv) compute an optimal dose that immediately creates and maintains maximal possible TC concentrations.**WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?**Developed model predicts delayed build‐up of TC concentration as the BsAb dose increases. A QE approximation with less parameters was constructed. Optimal working range of the TC is characterized that allows determination of an optimal dosing strategy.**HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?**Presented BsAb model can help in optimizing the design of BsAbs and selection of targets. Additionally, the BsAb model/approximation can be used to select an optimal dosing strategy.

 {#psp412369-sec-0001}

Bispecific antibodies (BsAbs) are promising therapeutic modalities that are being developed for different diseases, such as hematologic malignancies, hemophilia, Alzheimer's disease, and Ebola virus.[1](#psp412369-bib-0001){ref-type="ref"}, [2](#psp412369-bib-0002){ref-type="ref"}, [3](#psp412369-bib-0003){ref-type="ref"}, [4](#psp412369-bib-0004){ref-type="ref"} Currently, there are two clinically approved BsAbs: blinatumomab for acute lymphoblastic leukemia, and emicizumab for hemophilia A.[2](#psp412369-bib-0002){ref-type="ref"}, [4](#psp412369-bib-0004){ref-type="ref"} BsAbs induce pharmacological action via various mechanisms, such as bridging effector cells and target cells, modulating a pathway by simultaneously binding to two receptors, or by shuttling the molecule at the site‐of‐action. These effects are exerted via binding to soluble or membrane bound targets on the same/separate cells.[5](#psp412369-bib-0005){ref-type="ref"}, [6](#psp412369-bib-0006){ref-type="ref"} Consequently, regardless of the mechanism, all BsAbs have potential to exhibit target‐driven pharmacokinetics (PKs). Here, we have presented the development of a general target‐mediated drug disposition (TMDD) model[7](#psp412369-bib-0007){ref-type="ref"}, [8](#psp412369-bib-0008){ref-type="ref"}, [9](#psp412369-bib-0009){ref-type="ref"} for BsAbs using an immuno‐oncology molecule that binds to two different targets present on the membrane of two different cells.

A BsAb that binds to two different targets can form two binary complexes (BCs). Both of these BCs can further bind to the other target to form the ternary complex (TC). This TC is the pharmacologically active species that drives the pharmacodynamic (PD) effect of BsAbs (e.g., designed to redirect T cells toward cancer cells). Thus, TC concentration is pertinent for elucidating PD behavior of BsAbs.[10](#psp412369-bib-0010){ref-type="ref"}, [11](#psp412369-bib-0011){ref-type="ref"}

Development of a TMDD model for BsAbs is complicated due to the differences in kinetics and binding affinities of both targets. Several models have been developed to describe the PK of BsAbs that bind to cell surface or soluble targets by incorporating target density, turnover rates, affinity, and avidity parameters[12](#psp412369-bib-0012){ref-type="ref"}, [13](#psp412369-bib-0013){ref-type="ref"}, [14](#psp412369-bib-0014){ref-type="ref"}, [15](#psp412369-bib-0015){ref-type="ref"} and have been used to characterize plasma and tissue concentrations of BsAbs.[16](#psp412369-bib-0016){ref-type="ref"} However, all these models use parameters that are hard to accurately measure, such as the rapid processes like binding reactions and internalization/degradation of the complexes. Thus, there is need for a reliable approximation of a general BsAb model, which can characterize and predict the kinetics with less number of parameters.

Here, we have presented a general full TMDD model for BsAb. This model is applied to investigate the PK behavior of the TC and to explore an optimal dosing strategy, where optimality is defined by an immediate build‐up and maintenance of maximal TC concentration. The model consists of four binding events between six species, leading to the formation of BCs and TCs. It involves target turnover and degradation/internalization of the complexes. To reduce the number of model parameters, the quasi‐equilibrium (QE) approximation is constructed based on the fundamental assumption of rapid binding during all four binding events. This approach allows construction of the approximation that retains all model properties available in the full BsAb TMDD model. It is shown that the number of model parameters can be further reduced by assuming that the total receptor concentrations are constant. Furthermore, using the full model and its approximations allow us to reveal important model properties.

We investigated how the changes in target and antibody concentrations affect formation of TC. It is shown that larger doses delay the build‐up of the TC, and a method to compute the optimal dosing strategy that immediately creates and maintains the maximal TC concentration is presented. Finally, a simulation‐estimation study to address parameter identifiability is included.

Methods {#psp412369-sec-0002}
=======

Theoretical (model structure and equations) {#psp412369-sec-0003}
-------------------------------------------

Binding kinetics of the BsAb[12](#psp412369-bib-0012){ref-type="ref"}, [13](#psp412369-bib-0013){ref-type="ref"}, [14](#psp412369-bib-0014){ref-type="ref"}, [15](#psp412369-bib-0015){ref-type="ref"}, [16](#psp412369-bib-0016){ref-type="ref"} are presented in **Figure** [**1**](#psp412369-fig-0001){ref-type="fig"} **a**. It is assumed that free BsAb concentration *C binds* to two *targets* (e.g., receptors) *R* ~A~ and *R* ~B~ to form BCs, *RC* ~A~ and *RC* ~B~. Both *BCs* further cross‐link with the other target creating the TC *RC* ~AB~. Binding rates *k* ~onZ~ describe the binding of free drug to free receptor or BC, and *k* ~offZ~ describes the dissociation for *Z *=* *1, ..., 4.

![Schematic of bispecific binding kinetics (**a**), full bispecific target‐mediated drug disposition (TMDD) model (**b**), quasi‐equilibrium (QE) approximation (**c**), and QE approximation with total constant receptors (**d**). Solid boxes reflect the necessity of a differential equation for this state, and the dotted boxes reflect that these states are explicitly available. The peripheral compartment is marked as a dashed box.](PSP4-8-177-g001){#psp412369-fig-0001}

We extend the binding kinetics to establish a full BsAb model (**Figure** [**1**](#psp412369-fig-0001){ref-type="fig"} **b**). Receptors *R* ~A~ and *R* ~B~ are generated using zero‐order rates *k* ~synX~, and degraded at first‐order rates *k* ~degX~, where *X* denotes target *A* or *B*. All three formed complexes are assumed to internalize with rates *k* ~intY~, where *Y* stands for *A*,*B*, or *AB*. The drug is assumed to eliminate linearly from the central compartment with *k* ~el~, and distributes to the peripheral compartment *AP* via *k* ~12~ and *k* ~21~. Assuming high affinity to the targets and limited capacity of the targets, this model becomes the full BsAb TMDD model.

Models with such detailed mechanisms are usually overparameterized for application and approximations are necessary to reduce the number of parameters. A reasonable approximation reduces complexity of the mechanism but at the same time conserves as many properties of the original model as possible. Under the assumption of high affinity to its targets, rapid binding was assumed for all binding processes to construct the QE approximation (**Figure** [**1**](#psp412369-fig-0001){ref-type="fig"} **c**). This approximation can be further simplified by assuming either one or both total receptor concentrations are constant (**Figure** [**1**](#psp412369-fig-0001){ref-type="fig"} **d**), which further reduces the number of parameters.

Finally, properties of the TC are investigated and an optimal dosing strategy to ensure the maximal possible TC concentration is presented.

### Full BsAb model {#psp412369-sec-0004}

The equations for the full BsAb TMDD model (**Figure** [**1**](#psp412369-fig-0001){ref-type="fig"} **b**) read:

$$\frac{d}{dt}AD = \mathit{In}_{SC}{(f,t)} - k_{a}AD$$ $$\begin{array}{cl}
{\frac{d}{dt}C =} & {\frac{\mathit{In}_{IV}{(t)}}{V} + \frac{k_{a}\mathit{AD}}{V} - k_{el}C - k_{{on}1}C \cdot R_{A} + k_{{off}1}\mathit{RC}_{A}} \\
 & {- k_{{on}2}C \cdot R_{B} + k_{{off}2}\mathit{RC}_{B} - k_{12}C + k_{21}\frac{\mathit{AP}}{V}} \\
\end{array}$$ $$\begin{array}{cl}
{\frac{d}{dt}R_{A} = \,} & {k_{synA} - k_{degA}R_{A} - k_{{on}1}C \cdot R_{A} + k_{{off}1}\mathit{RC}_{A}} \\
 & {- k_{{on}4}\mathit{RC}_{B} \cdot R_{A} + k_{{off}4}\mathit{RC}_{AB}} \\
\end{array}$$ $$\begin{array}{cl}
{\frac{d}{dt}R_{B} = \,} & {k_{synB} - k_{degB}R_{B} - k_{{on}2}C \cdot R_{B} + k_{{off}2}\mathit{RC}_{B}} \\
 & {- k_{{on}3}\mathit{RC}_{A} \cdot R_{B} + k_{{off}3}\mathit{RC}_{AB}} \\
\end{array}$$ $$\frac{d}{dt}\mathit{RC}_{A} = k_{{on}1}C \cdot R_{A} - {(k_{{off}1} + k_{intA})}\mathit{RC}_{A} - k_{{on}3}\mathit{RC}_{A} \cdot R_{B} + k_{{off}3}\mathit{RC}_{AB}$$ $$\frac{d}{dt}\mathit{RC}_{B} = k_{{on}2}C \cdot R_{B} - {(k_{{off}2} + k_{intB})}\mathit{RC}_{B} - k_{{on}4}\mathit{RC}_{B} \cdot R_{A} + k_{{off}4}\mathit{RC}_{AB}$$ $$\frac{d}{dt}\mathit{RC}_{AB} = k_{{on}4}\mathit{RC}_{B} \cdot R_{A} + k_{{on}3}\mathit{RC}_{A} \cdot R_{B} - {(k_{{off}3} + k_{{off}4} + k_{intAB})}\mathit{RC}_{AB}$$ $$\frac{d}{dt}AP = k_{12}V \cdot C - k_{21}AP$$

where *In* ~IV~ and *In* ~SC~ are input functions of i.v. and s.c. administration of drug amount, *f* denotes bioavailability, and *V* is volume of distribution.

Since BsAbs are engineered molecules, the BsAbs will not be endogenously available prior to treatment. Therefore, existence of an endogenous BsAb baseline was omitted. This implies no or at least negligible endogenous concentration of the mAbs. Consequently, initial values for Eqs. [(1)](#psp412369-disp-0001){ref-type="disp-formula"}−8 are:

$$AD{(0)} = 0,\quad C{(0)} = 0,\, R_{X}{(0)} = \frac{k_{synX}}{k_{degX}},\,\mathit{RC}_{Y}{(0)} = 0\quad\text{and}\,\; AP{(0)} = 0.$$

The full BsAb model Eqs. [(1)](#psp412369-disp-0001){ref-type="disp-formula"}−9 consists of 19 parameters:

$$\begin{array}{cl}
{\theta =} & {(k_{synA},k_{degA},k_{synB},k_{degB},k_{intA},k_{intB},k_{intAB},\, k_{{on}1},k_{{off}1},} \\
 & {k_{{on}2},k_{{off}2},k_{{on}3},k_{{off}3},k_{{on}4},k_{{off}4},\, k_{el},k_{12},k_{21},V)} \\
\end{array}$$

Total BsAb concentration and total receptor variables read:

$$C_{tot} = C + \mathit{RC}_{A} + \mathit{RC}_{B} + \mathit{RC}_{AB}$$ $$R_{totA} = R_{A} + \mathit{RC}_{A} + \mathit{RC}_{AB}$$ $$R_{totB} = R_{B} + \mathit{RC}_{B} + \mathit{RC}_{AB}$$

### QE approximation of the BsAb model {#psp412369-sec-0005}

Rapid binding for the four binding events is approximated with the QE method,[9](#psp412369-bib-0009){ref-type="ref"} ^,^ [17](#psp412369-bib-0017){ref-type="ref"} which means that rapid binding is described by an infinitely fast binding process resulting in a binding equilibrium. Binding rates *k* ~onZ~ and *k* ~offZ~ are substituted by their equilibrium (dissociation) constant:$$K_{DZ} = \frac{k_{offZ}}{k_{onZ}}$$

According to the principle of microscopic reversibility,[18](#psp412369-bib-0018){ref-type="ref"} in a cyclic reaction mechanism, the individual reactions must balance itself in equilibrium condition by enforcing:$$K_{D1}K_{D3} = K_{D2}K_{D4}$$

This is equivalent to *K* ~D3~ = α*K* ~D2~ and *K* ~D4~ = α*K* ~D1~, where α denotes the affinity between *C* and *RC* ~B~ for *R* ~A~, or *C* and *RC* ~A~ for *R* ~B~. Thus, rapid binding is completely described by only three parameters *K* ~D1~, *K* ~D2~, and α.

The QE approximation reads:$$\frac{d}{dt}AD = In_{SC}\left( {f,t} \right) - k_{a}AD$$ $$\begin{pmatrix}
{\frac{d}{dt}C} \\
{\frac{d}{dt}R_{A}} \\
{\frac{d}{dt}R_{B}} \\
\end{pmatrix} = M_{BsAb}{(C,R_{A},R_{B})} \cdot g_{BsAb}{(\mathit{AD},C,R_{A},R_{B},\mathit{AP})}$$ $$\frac{d}{dt}AP = k_{12}V \cdot C - k_{21}AP$$where matrix *M* ~BsAb~ (*C*,*R* ~A~, *R* ~B~) is of the form:$$M_{BsAb}{(C,R_{A},R_{B})} = \frac{1}{\mathit{\det}}\begin{pmatrix}
m_{11} & m_{12} & m_{13} \\
m_{21} & m_{22} & m_{23} \\
m_{31} & m_{32} & m_{33} \\
\end{pmatrix}$$with the determinant *det*. Entries *m* ~ij~ and determinant *det* are listed in **Table** [**1**](#psp412369-tbl-0001){ref-type="table"}. Vector *g* ~BsAb~ (*AD*,*C*,*R* ~A~, *R* ~B~, *AP*) reads:$$g_{BsAb}{(AD,C,R_{A},R_{B},AP)} = \begin{pmatrix}
{\frac{In_{IV}{(t)}}{V} + \frac{k_{\alpha}AD}{V} - k_{el}C - k_{intA}\frac{R_{A}C}{K_{D1}} - k_{\mathit{intB}}\frac{R_{B}C}{K_{D2}} - k_{intAB}\frac{R_{A}R_{B}C}{\alpha K_{D1}K_{D2}} - k_{12}C + k_{21}\frac{\mathit{AP}}{V}} \\
{k_{synA} - k_{degA}R_{A} - k_{intA}\frac{R_{A}C}{K_{D1}} - k_{intAB}\frac{R_{A}R_{B}C}{\alpha K_{D1}K_{D2}}} \\
{k_{synB} - k_{degB}R_{B} - k_{intB}\frac{R_{B}C}{K_{D2}} - k_{intAB}\frac{R_{A}R_{B}C}{\alpha K_{D1}K_{D2}}} \\
\end{pmatrix}$$

###### 

**Determinant and entries for the matrix** ***M*** ~**BsAb**~ **(** ***C*** **,** ***R*** ~**A**~ **,** ***R*** ~**B**~ **) in Eq.** [**18**](#psp412369-disp-0019){ref-type="disp-formula"} **of the quasi‐equilibrium approximation**

  ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  det =        (C\*KD2\*RA\^2 + C\^2\*KD2\*RA + C\*KD1\*RB\^2 + C\^2\*KD1\*RB + C\^2\*RA\*RB + a\*KD1\^2\*KD2\^2 + C\*KD1\*KD2\*RA + C\*KD1\*KD2\*RB + KD1\*KD2\*RA\*RB + a\*C\*KD1\*KD2\^2 + a\*C\*KD1\^2\*KD2 + a\*C\^2\*KD1\*KD2 + a\*KD1\*KD2\^2\*RA + a\*KD1\^2\*KD2\*RB + a\*C\*KD1\*KD2\*RA + a\*C\*KD1\*KD2\*RB)/(a\*KD1\^2\*KD2\^2)
  *m* ~11~ =   (C\^2\*KD2\*RA + C\^2\*KD1\*RB + a\*KD1\^2\*KD2\^2 + C\*KD1\*KD2\*RA + C\*KD1\*KD2\*RB + a\*C\*KD1\*KD2\^2 + a\*C\*KD1\^2\*KD2 + a\*C\^2\*KD1\*KD2)/(a\*KD1\^2\*KD2\^2)
  *m* ~12~ =   −(C\^2\*RA + C\*KD1\*RB + a\*C\^2\*KD1 + a\*C\*KD1\*KD2)/(a\*KD1\^2\*KD2)
  *m* ~13~ =   −(C\^2\*RB + C\*KD2\*RA + a\*C\^2\*KD2 + a\*C\*KD1\*KD2)/(a\*KD1\*KD2\^2)
  *m* ~21~ =   −(C\*RA\^2 + KD1\*RA\*RB + a\*C\*KD1\*RA + a\*KD1\*KD2\*RA)/(a\*KD1\^2\*KD2)
  *m* ~22~ =   (C\*RA\^2 + C\*KD1\*RA + KD1\*RA\*RB + a\*C\*KD1\^2 + a\*KD1\^2\*KD2 + a\*KD1\^2\*RB + a\*C\*KD1\*RA + a\*KD1\*KD2\*RA)/(a\*KD1\^2\*KD2)
  *m* ~23~ =   −(C\*RA − a\*C\*RA)/(a\*KD1\*KD2)
  m~31~ =      −(C\*RB\^2 + KD2\*RA\*RB + a\*C\*KD2\*RB + a\*KD1\*KD2\*RB)/(a\*KD1\*KD2\^2)
  *m* ~32~ =   −(C\*RB − a\*C\*RB)/(a\*KD1\*KD2)
  *m* ~33~ =   (C\*RB\^2 + C\*KD2\*RB + KD2\*RA\*RB + a\*C\*KD2\^2 + a\*KD1\*KD2\^2 + a\*KD2\^2\*RA + a\*C\*KD2\*RB + a\*KD1\*KD2\*RB)/(a\*KD1\*KD2\^2)
  ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Parameter α is denoted by *a*.
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Explicit equations for the complexes read:$$\mathit{RC}_{A} = \frac{C \cdot R_{A}}{K_{D1}}$$ $$\mathit{RC}_{B} = \frac{C \cdot R_{B}}{K_{D2}}$$ $$\mathit{RC}_{AB} = \frac{C \cdot R_{A} \cdot R_{B}}{\alpha K_{D1}K_{D2}}$$

Note, with *K* ~D1~ = *K* ~D4~ and *K* ~D2~ = *K* ~D3~ we have α = 1. Initial values for the QE approximation Eqs. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(16)](#psp412369-disp-0017){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, [(18)](#psp412369-disp-0019){ref-type="disp-formula"}, [(19)](#psp412369-disp-0020){ref-type="disp-formula"} are equal to those from the full model Eq. [(9)](#psp412369-disp-0009){ref-type="disp-formula"}. The number of parameters reduces to 14:$$\begin{array}{cl}
{\theta =} & {({k_{synA},k_{degA},k_{synB},k_{degB},k_{intA},k_{intB},k_{intAB},}} \\
 & {{\alpha,K_{D1},K_{D2},k_{el},k_{12},k_{21},V})} \\
\end{array}$$

Derivation of Eqs. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(16)](#psp412369-disp-0017){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, [(18)](#psp412369-disp-0019){ref-type="disp-formula"}, [(19)](#psp412369-disp-0020){ref-type="disp-formula"}, [(20)](#psp412369-disp-0021){ref-type="disp-formula"}, [(21)](#psp412369-disp-0022){ref-type="disp-formula"}, [(22)](#psp412369-disp-0023){ref-type="disp-formula"} is provided in **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}.

The applied infinitely fast binding process in the QE approximation splits the i.v. administered drug into the part that is immediately bound in the BCs and TC, and the remaining part that is available as free BsAb concentration. This is reflected by multiplication of the input function *In* ~*IV*~(*t*) with factors depending on free BsAb concentration and free receptors. Additionally, *In* ~*IV*~(*t*) acts on the receptor states (compare matrix multiplication in Eqs. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(16)](#psp412369-disp-0017){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, [(18)](#psp412369-disp-0019){ref-type="disp-formula"}, [(19)](#psp412369-disp-0020){ref-type="disp-formula"}). An appropriate implementation of the QE approximation for i.v. dosing in standard PK/PD software is presented in the Modeling and Simulation section.

### QE and constant total receptor approximation of the BsAb model {#psp412369-sec-0006}

Further reduction of parameters is possible with the assumption that total receptor concentrations are constant. The relationship

$$k_{degX} = k_{intX} = k_{intAB} = :k_{int}$$

provides

$$R_{totX} \equiv R_{totX}^{0} = \frac{k_{synX}}{k_{degX}}$$

for both, the full BsAb model and its QE approximation, *X *= *A*,*B*. Implementation of this approximation can be provided in two ways. On one hand, the relationship from Eq. [(23)](#psp412369-disp-0025){ref-type="disp-formula"} can be used in Eqs. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(16)](#psp412369-disp-0017){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, [(18)](#psp412369-disp-0019){ref-type="disp-formula"}, [(19)](#psp412369-disp-0020){ref-type="disp-formula"}, [(20)](#psp412369-disp-0021){ref-type="disp-formula"}, [(21)](#psp412369-disp-0022){ref-type="disp-formula"}, [(22)](#psp412369-disp-0023){ref-type="disp-formula"}. On the other hand, an equivalent model can be constructed consisting of one differential equation for free BsAb:

$$\begin{aligned}
{\frac{d}{dt}C =} & {\frac{m_{11}}{\mathit{\det}}\left( {\frac{\mathit{In}_{\mathit{IV}}{(t)}}{V} + \frac{k_{a}AD}{V} - k_{el}C - k_{int}\frac{R_{A}C}{K_{D1}} - k_{int}\frac{R_{B}C}{K_{D2}} - k_{int}\frac{R_{A}R_{B}C}{\alpha K_{D1}K_{D2}} - k_{12}C + k_{21}\frac{\mathit{AP}}{V}} \right)} \\
\end{aligned}$$

with the explicit representations

$$R_{A} = \frac{R_{totA}^{0}}{1 + \frac{C}{K_{D1}} + \frac{R_{B}C}{\alpha K_{D1}K_{D2}}}$$

and

$$R_{B} = \begin{cases}
R_{totB}^{0} & {for\; C = 0} \\
\frac{\left( {- b + \sqrt{b^{2} - 4ad}} \right)}{2a} & {for\; C > \, 0} \\
\end{cases}$$

where

$$a = \left( {1 + \frac{C}{K_{D2}}} \right)\frac{C}{\alpha K_{D1}K_{D2}}$$

$$b = \frac{C\left( {R_{totA}^{0} - R_{totB}^{0}} \right)}{\alpha K_{D1}K_{D2}} + \left( {1 + \frac{C}{K_{D2}}} \right)\left( {1 + \frac{C}{K_{D1}}} \right)$$ $$d = - R_{totB}^{0}\left( {1 + \frac{C}{K_{D1}}} \right)$$

along with Eqs. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, see **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"} for derivation. The number of parameters now reduces to 10:

$$\theta = \left( {R_{totA}^{0},R_{totB}^{0},k_{int},\alpha,K_{D1},K_{D2},k_{el},k_{12},k_{21},V} \right)$$

### BsAb concentration‐TC relationship {#psp412369-sec-0007}

The TC drives the PD effect of BsAbs. Hence, achieving maximal TC concentration will be ideal to observe maximum PD effect.[10](#psp412369-bib-0010){ref-type="ref"}, [11](#psp412369-bib-0011){ref-type="ref"} To develop an optimal dosing strategy, the BsAb concentration‐TC relationship is applied. Li *et al*.[19](#psp412369-bib-0019){ref-type="ref"} developed the equilibrium binding (EB) model, describing pure binding relations, which is the QE model, Eqs. [(16)](#psp412369-disp-0017){ref-type="disp-formula"}, [(18)](#psp412369-disp-0019){ref-type="disp-formula"}, [(19)](#psp412369-disp-0020){ref-type="disp-formula"}, [(20)](#psp412369-disp-0021){ref-type="disp-formula"}, [(21)](#psp412369-disp-0022){ref-type="disp-formula"}, [(22)](#psp412369-disp-0023){ref-type="disp-formula"}, completed with$$0 = k_{degX} = k_{synX} = k_{intX} = k_{el} = k_{12} = k_{21} = k_{a},\quad 0 = k_{intY}.$$

This is similar to the closed (*in vitro*) system in case of a standard monoclonal antibody TMDD model[20](#psp412369-bib-0020){ref-type="ref"}, [21](#psp412369-bib-0021){ref-type="ref"}, [22](#psp412369-bib-0022){ref-type="ref"} and can be for the BsAb model equivalently formulated in stationary form by Eqs. 20--22 and 26--30 (see **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}).

For any *C* and any *R* ~totA~ and *R* ~totB~, the EB model admits an equilibrium description:$$\left( {C,R_{A}{(C)},R_{B}{(C)},RC_{A}{(C)},RC_{B}{(C)},RC_{AB}{(C)}} \right)$$with *R* ~A~, *R* ~B~ according to Eqs. [(20)](#psp412369-disp-0021){ref-type="disp-formula"}−22 and 26−30.

More precisely, we obtain the free BsAb concentration‐TC relationship (*C*,*RC* ~AB~ (*C*)) as:$$\mathit{RC}_{AB}{(C)} = \frac{C \cdot R_{A}{(C)} \cdot R_{B}{(C)}}{\alpha K_{D1}K_{D2}}$$ $$= \frac{\mathit{RC}_{A}{(C)}\mathit{RC}_{B}{(C)}}{\alpha C}$$with parameters θ = (*R* ~totA~, *R* ~totB~, α, *K* ~D1~, *K* ~D2~). Eq. [(33)](#psp412369-disp-0036){ref-type="disp-formula"} is the equivalent analytical representation of the TC concentration described by Li *et al*.[19](#psp412369-bib-0019){ref-type="ref"} with an implicit system. For low free BsAb concentrations, TC Eq. [(33)](#psp412369-disp-0036){ref-type="disp-formula"} increases, whereas in contrast to classical concentration‐effect terms,[23](#psp412369-bib-0023){ref-type="ref"}, [24](#psp412369-bib-0024){ref-type="ref"} TC concentration decreases and finally vanishes for high BsAb concentrations, that is:

$$\lim\limits_{C\rightarrow\infty}\mathit{RC}_{\text{AB}}{(C)} = 0$$

(see **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}). This phenomenon is due to the cross‐linking reactions. At higher concentrations of BsAb, all receptors are occupied, which interferes in formation of the TC. Hence, *RC* ~A~ and *RC* ~B~ saturate at *R* ~totA~ and *R* ~totB~, and therefore, Eq. [(34)](#psp412369-disp-0037){ref-type="disp-formula"} enforces Eq. [(35)](#psp412369-disp-0038){ref-type="disp-formula"}.

Structural properties of the TC now become visible, provided the TC concentration is visualized (compare ref. [19](#psp412369-bib-0019){ref-type="ref"}) in the total BsAb concentration‐TC relationship:$$(C_{tot}{(C)},\,\mathit{RC}_{AB}{(C)})$$diagram for fixed given values of *R* ~totA~ and *R* ~totB~, see **Figure** [**2**](#psp412369-fig-0002){ref-type="fig"} **a**, in which the typical bell‐shaped profile is shown. This diagram suggests an optimal TC concentration, if total BsAb concentration satisfies:$$\min\left( {R_{totA},R_{totB}} \right) \leq C_{tot} \leq \max\left( {R_{totA},R_{totB}} \right).$$

![Diagram showing the relationship between total bispecific antibody (BsAb) concentration *C* ~tot~ and the ternary complex *RC* ~*AB*~ simulated with the equilibrium binding model. (**a**) The typical bell‐shaped curve is shown, and the area between the dashed bars shows the optimal working range of the BsAb. Parameter settings are K~D~ ~1~ = K~D~ ~2~ = 0.01 nM, $R_{totA}^{0}$ = 10 nM, $R_{totB}^{0}$ = 100 nM and α = 1. To visualize the effect of varying parameter values, only one parameter is changed at a time, over a wide range. Further the *y*‐axis was normalized. (**b and c**) The effect of K~D~ ~1~ and K~D~ ~2~ is shown, (**d**) the effect of α, (**e**) the effect of $R_{totA}^{0}$.](PSP4-8-177-g002){#psp412369-fig-0002}

Hence, the relation in Eq. [(36)](#psp412369-disp-0040){ref-type="disp-formula"} defines the optimal working range of the BsAb.

### Optimal dosing strategy for maximal TC concentration {#psp412369-sec-0008}

The solutions of the QE approximation and the EB model both satisfy the same algebraic Eqs. [(20)](#psp412369-disp-0021){ref-type="disp-formula"}, [(21)](#psp412369-disp-0022){ref-type="disp-formula"}, [(22)](#psp412369-disp-0023){ref-type="disp-formula"}. Thus, any solution of the QE model at an arbitrary time point *t* ~p~ with $R_{totX}{(t_{p})} = R_{totX}^{0}$ and $C_{tot}{(t_{p})} = C_{tot}^{0}$ coincides with the EB model solution Eq. [(32)](#psp412369-disp-0035){ref-type="disp-formula"} with $C_{tot}{(C)} = C_{tot}^{0}$. This allows us to translate dynamical properties from the EB model to the QE approximation and the full model. It means that, in the QE model, the binding parameters characterize the algebraic relationship Eqs. [(20)](#psp412369-disp-0021){ref-type="disp-formula"}, [(21)](#psp412369-disp-0022){ref-type="disp-formula"}, [(22)](#psp412369-disp-0023){ref-type="disp-formula"} and target turnover, elimination and internalization rates determine the values of *R* ~totX~ and *C* ~tot~ or *C* for which Eq. [(32)](#psp412369-disp-0035){ref-type="disp-formula"} is evaluated.

Using this relationship between QE and EB model and Eq. [(36)](#psp412369-disp-0040){ref-type="disp-formula"}, an optimal dosing strategy realizing a high TC concentration in the QE approximation must satisfy$$\min\left( {R_{totA}\left( t \right),R_{totB}\left( t \right)} \right) \leq C_{tot}\left( t \right) \leq \max\left( {R_{totA}\left( t \right),R_{totB}\left( t \right)} \right)$$for as many *t* values as possible.

In case of constant total receptors and *k* ~el~ = *k* ~int~ optimal doses and re‐dosing timepoints can be computed explicitly assuring maximal TC concentration. For i.v. bolus administration with no peripheral compartment, we derive (**Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}):$$C_{tot}\left( t \right) = C^{0} \cdot \exp\left( {- k_{el} \cdot t} \right)$$where *C* ^0^ is the initial free BsAb concentration. Eq. [(36)](#psp412369-disp-0040){ref-type="disp-formula"} implies $C_{tot}{(0)}$ = $\max\left( {R_{totA}^{0},R_{totB}^{0}} \right)$ and we obtain the optimal BsAb amount for the initial dose

$$\text{dose}_{init} = \max\left( {R_{totA}^{0},R_{totB}^{0}} \right) \cdot V.$$

The re‐dosing timepoint is defined by $\min{(R_{totA}^{0},R_{totB}^{0})} = C_{tot}{(t_{opt})}$ and we compute

$$t_{opt} = \frac{1}{k_{el}}\ln\left( \frac{C^{0}}{\min\left( {R_{totA},R_{totB}} \right)} \right).$$

All subsequent doses are$$\text{dose}_{seq} = \left( {\max\left( {R_{totA}^{0},R_{totB}^{0}} \right) - \min\left( {R_{totA}^{0},R_{totB}^{0}} \right)} \right) \cdot V$$with multiples of *t* ~opt~ for the re‐dosing timepoints.

In general, in full or QE models, the total amount of receptors *A* and *B* evolves in time. Nevertheless, an optimal dosing strategy has to generate a total drug concentration satisfying Eq. [(37)](#psp412369-disp-0041){ref-type="disp-formula"} for as many *t* values as possible. The optimal initial dose is again given by Eq. [(39)](#psp412369-disp-0043){ref-type="disp-formula"}. However, an optimal re‐dosing timepoint cannot be explicitly calculated anymore. But the optimal re‐dosing timepoint can be identified when *C* ~tot~(*t*) leaves the optimal working range defined by the timepoint *t* ~opt~ satisfying$$\min\left( {R_{totA}\left( t_{opt} \right),R_{totB}\left( t_{opt} \right)} \right) = C_{tot}\left( t_{opt} \right).$$

All following optimal doses are$$\begin{array}{cl}
{\text{dose}_{seq} =} & {({\max({R_{totA}(t_{opt}),R_{totB}(t_{opt})})}} \\
 & {{- \min({R_{totA}(t_{opt}),R_{totB}(t_{opt})})}) \cdot V.} \\
\end{array}$$

This method allows identification of an optimal dosing strategy for the full model or its QE approximation, provided the model parameter values are known. The basis is the validity of the rapid binding assumption, because singular perturbation theory[25](#psp412369-bib-0025){ref-type="ref"} guarantees that (i) dynamics of the full model and its QE approximation are nearly identical, and (ii) solutions of the QE model in the BCs and TC move along the predictions of the EB model.

Modeling and simulation {#psp412369-sec-0009}
-----------------------

### Parameter setting for simulations {#psp412369-sec-0010}

Applied parameters for pure simulations to reveal profile properties and parameters and results for the simulation‐estimation study are presented in **Table** [**2**](#psp412369-tbl-0002){ref-type="table"}. All parameters were roughly based on literature reported values[19](#psp412369-bib-0019){ref-type="ref"}, [26](#psp412369-bib-0026){ref-type="ref"}, [27](#psp412369-bib-0027){ref-type="ref"}, [28](#psp412369-bib-0028){ref-type="ref"} (conversion factor 1 mg = 6.7 nM). Other applied parameters are mentioned in the text. Typical absolute i.v. bolus doses used are 50 mg and up to 700 mg for s.c. For simulations, a lower limit of quantification (LLOQ) of 0.01 nM was assumed.

###### 

Parameter values for pure simulations (left part) and the simulation‐estimation study including results (right part)

  Simulation    Simulation‐estimation study                                                                                                                                                                                                                                                                                                                
  ------------- ----------------------------- ------ --------------------------------------------------- ------- --------------------------------------------- --------------------------------------------- ----------------------------------------------- ----------------------------------------------- --------------------------------------------- -------------------------------------------
  *V*           L                             3      *k* ~el~                                            1/day   0.1                                           0.15                                          0.126                                           0.118                                           0.104                                         0.104
  *k* ~a~       1/day                         0.2    *K* ~D1~ [b](#psp412369-note-0005){ref-type="fn"}   nM      0.1                                           0.2                                           0.1[^a^](#psp412369-note-0005){ref-type="fn"}   0.1[^a^](#psp412369-note-0005){ref-type="fn"}   0.114                                         0.13
  *F*           --                            0.75   *K* ~D2~ [b](#psp412369-note-0005){ref-type="fn"}   nM      1                                             0.5                                           1[^a^](#psp412369-note-0005){ref-type="fn"}     1[^a^](#psp412369-note-0005){ref-type="fn"}     1.05                                          1.04
  *k* ~el~      1/day                         0.1    α                                                   --      1[^a^](#psp412369-note-0005){ref-type="fn"}   1[^a^](#psp412369-note-0005){ref-type="fn"}   1[^a^](#psp412369-note-0005){ref-type="fn"}     1[^a^](#psp412369-note-0005){ref-type="fn"}     1[^a^](#psp412369-note-0005){ref-type="fn"}   1[a](#psp412369-note-0005){ref-type="fn"}
  *k* ~12~      1/day                         0.1    $R_{A}^{0}$                                         nM      10                                            15                                            7.05                                            8.18                                            9.78                                          9.79
  *k* ~21~      1/day                         0.03   $R_{B}^{0}$                                         nM      100                                           80                                            78.3                                            87.5                                            100                                           100
  *k* ~on1~     1/(nM day)                    10     *k* ~int~                                           1/day   0.1                                           0.1                                           0.105                                           0.103                                           0.100                                         0.100
  *k* ~off1~    1/day                         0.01   *V*                                                 L       3                                             2.5                                           2.73                                            2.73                                            2.84                                          2.85
  *k* ~on2~     1/(nM day)                    1      *ω* ~kel~                                           --      0.05                                          1                                             0.045                                           0.049                                           0.023                                         0.010
  *k* ~off2~    1/day                         0.01   *ω* ~V~                                             --      0.05                                          1                                             0.058                                           0.056                                           0.065                                         0.066
  $R_{A}^{0}$   nM                            10     *b* ~1~                                             --      0.2                                           0.3                                           0.206                                           0.205                                           0.210                                         0.211
  $R_{B}^{0}$   nM                            100    *b* ~2~                                             --      0.2                                           0.3                                           ---                                             ---                                             0.206                                         0.206
  *k* ~synA~    nM/day                        1      *b* ~3~                                             --      0.2                                           0.3                                           ---                                             ---                                             0.207                                         0.207
  *k* ~degA~    1/day                         0.1                                                                                                                                                                                                                                                                                                          
  *k* ~synB~    nM/day                        10                                                                                                                                                                                                                                                                                                           
  *k* ~degB~    1/day                         0.1                                                                                                                                                                                                                                                                                                          
  *k* ~intA~    1/day                         0.05                                                                                                                                                                                                                                                                                                         
  *k* ~intB~    1/day                         0.05                                                                                                                                                                                                                                                                                                         
  *k* ~intAB~   1/day                         0.1                                                                                                                                                                                                                                                                                                          

^a^Parameter value was fixed during estimation. ^b^True values in the full model were (*k* ~on1~, *k* ~off1~) = (10,1), (*k* ~on2~, *k* ~off2~) = (1,1), (*k* ~synA~, *k* ~degA~) = (1,0.1), (*k* ~synB~, *k* ~degB~) = (10,0.1) and (*k* ~intA~, *k* ~intB~, *k* ~intAB~) = (0.1,0.1,0.1).

Definitions of all parameters are presented in the text. For simplicity, we assume *k* ~on3~ = *k* ~on2~, *k* ~on4~ = *k* ~on1~, *k* ~off3~ = *k* ~off2~, and *k* ~off4~ = *k* ~off1~. In study 1, data from free bispecific antibody concentration *C* was refitted. In study 2, data from *C* and the free receptors *R* ~A~ and *R* ~B~ was refitted. Standard deviations of the log‐normally distributed interindividual variability are *ω* ~V~ and $\omega_{k_{el}}$. Model parameters of the proportional residual error model are *b* ~1~, *b* ~2~, and *b* ~3~. Relative standard errors were all below 5% except for the SDs of the interindividual variability (below 100%) and are, therefore, not reported.

John Wiley & Sons, Ltd

### Implementation of the QE approximation with an i.v. administration {#psp412369-sec-0011}

In the QE approximation, with or without constant total receptors, the i.v. input function *In* ~*IV*~(*t*) is multiplied with different model states and appears at different positions in the equations (compare matrix multiplication in Eqs. [(16)](#psp412369-disp-0017){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, [(18)](#psp412369-disp-0019){ref-type="disp-formula"}, [(19)](#psp412369-disp-0020){ref-type="disp-formula"}). This affects implementation of i.v. bolus and infusion dosing.

Most standard PK/PD software, such as NONMEM (Icon, Ellicott City, MD) or MONOLIX (Lixoft, Orsay, France), handle drug administration internally with the consequence that the user is not allowed to freely position *In* ~*IV*~(*t*) in the code. More precisely, NONMEM or MONOLIX integrates the ordinary differential equation (ODE) system until the dosing timepoint. In case of i.v. bolus, the dose is added to the drug concentration state and solving the ODE system is continued. In case of i.v. infusion, the infusion rate is added to the right‐hand side of the corresponding ODE. These mechanisms can no longer be used for QE/quasi‐steady state approximations of more complex models, because *In* ~*IV*~(*t*) is multiplied with different model states and appears at different positions in the equations. Hence, the user has to implement an infusion mechanism. Having this mechanism, an i.v. bolus can be mimicked with a short infusion.

Implementation of an infusion mechanism can be "hard‐coded" by hand[17](#psp412369-bib-0017){ref-type="ref"}, [29](#psp412369-bib-0029){ref-type="ref"}: TDUR = 1e0; duration of infusion, for an i.v. bolus TDUR ; has to be set very small IN = 0 ; input function for infusion ; ‐‐‐ Administration of a dose = 335 starting from ; t = 0 IF (T.GE.0. AND T.LE.0+TDUR) THEN IN = 335\*TDUR\*\*(‐1) ENDIF

Now *In* ~*IV*~(*t*), described by IN, can be positioned everywhere in the code and multiplied with model states. Dummy timepoints at the start (here *t *=* *0) and end of infusion (here *t *= *t* ~dur~) might be necessary in the dataset for some software to correctly stop and continue integration.

Another possibility is to use a dummy compartment *In* ~IVDum~ $$\frac{d}{dt}\mathit{In}_{IVDum}{(t)} = 0\quad\mathit{In}_{IVDum}{(0)} = 0$$to mimic the input function *In* ~*IV*~(*t*). With the Tlag and "bioavailability" option, Eq. [(42)](#psp412369-disp-0048){ref-type="disp-formula"} is controlled with the administrations given in the dataset.

One remark is necessary for an i.v. bolus mimicked by a short i.v. infusion. In case of an i.v. bolus administered drug at *t *=* *0, we often also have a measurement at *t *=* *0 and, therefore, *C*(0) \> 0. In PK/PD software, an i.v. bolus at *t *=* *0 is implemented as *C*(0) = *C* ~0~ + $\frac{\text{dose}}{V}$, where *C* ~0~ = 0 is the initial condition of the free concentration ODE. However, if we mimic i.v. bolus by a short i.v. infusion, we have *C*(0) = *C* ^0^ = 0. This may lead to inconsistencies and consequently to numerical difficulties. To overcome this issue, we suggest to slightly shift the measurement in time (e.g., from *t *=* *0 to *t *=* *0.001).

In case of an absorption compartment, the internal dosing mechanisms from the PK/PD software can be used as usual due to the structure of Eq. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}.

NONMEM and MONOLIX code for the full BsAb model and its approximations with different administrations are available in the **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}.

Results {#psp412369-sec-0012}
=======

Simulations with the full BsAb model {#psp412369-sec-0013}
------------------------------------

To visualize the relationship between the BsAbs and the TC, simulations for 50 and 250 mg i.v. doses were performed, using the full model without peripheral compartment. Three properties become visible (**Figure** [**3**](#psp412369-fig-0003){ref-type="fig"}): (i) for the two different doses, area under the curve (AUC) of the BsAb concentration was much larger (400 times in this example) compared to AUC of the TC (1.5 times), (ii) the lower dose causes an immediate build‐up of the TC, whereas the higher dose produced a delayed build‐up, and (iii) TC formed is much longer available over time for both doses compared to the free BsAb concentration.

![Comparison of the free bispecific antibody (BsAb) concentration *C* and the ternary complex concentration *RC*~AB~ simulated with the full model. (**a**) The free BsAb concentration for two different i.v. bolus doses 50 mg (solid line) and 250 mg (dash‐dotted line). (**b**) Visualizes the effect on the build‐up of the ternary complex.](PSP4-8-177-g003){#psp412369-fig-0003}

To present the behavior of all six components *C*,*R* ~A~, *R* ~B~, *RC* ~*A*~, *RC* ~*B*~, and *RC* ~*AB*~ and to demonstrate the effects of the targets on the free BsAbs concentration profiles, a large i.v. dose of 500, and a large range for free BsAb concentration visualization was used (**Figure** [**4**](#psp412369-fig-0004){ref-type="fig"}). First, a linear elimination followed by a nonlinear elimination phase around *t* = 15 was observed. After an inflection point, these phases are followed again by a linear phase and a nonlinear elimination phase at *t* = 55 followed by a second inflection point. Onsets of recovery of the two targets cause the nonlinear elimination phases and affect the profile of the complexes (**Figure** [**4**](#psp412369-fig-0004){ref-type="fig"}). Effects of varying elimination rate on BsAb concentration and varying internalization rates on all concentration states are shown in **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}.

![Overall behavior of all six model components *C*,*R*~A~,*R*~B~,*RC*~A~,*RC*~B~, and *RC*~AB~ simulated with the full model. The effect of recovery of the free receptors *R*~A~ and *R*~B~ on the free bispecific antibody concentration *C* is shown and the relation to the complexes *RC*~A~,*RC*~B~ and *RC*~AB~ can be observed.](PSP4-8-177-g004){#psp412369-fig-0004}

Comparison of QE approximation with full BsAb model {#psp412369-sec-0014}
---------------------------------------------------

The approximations assume rapid binding. Therefore, absolute parameter values of *k* ~onX~, *k* ~offX~ play an essential role. We observed that increasing values for *k* ~onX~, *k* ~offX~, but with the same *K* ~*DX*~, shifts the full model toward the QE approximation, because the approximation only depends on *K* ~*DX*~. Free BsAb profiles using full model and approximation, without peripheral compartment and with i.v. bolus, are usually indistinguishable. However, depending on (i) inclusion of a peripheral compartment, (ii) route of administration, and (ii) dose amount, large values of *k* ~onX~, *k* ~offX~ may be needed. Examples are shown in **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}.

Two simulation‐estimation studies {#psp412369-sec-0015}
---------------------------------

In the first study, free BsAb profiles *C* for 30 individuals (12 measurements each over 40 days) were simulated with the full model until LLOQ was reached. In addition, free concentrations of both receptors *R* ~A~ and *R* ~B~ (18 measurements each over 70 days) were simulated with the full model until full recovery in the second study. Both datasets were refitted using the QE approximation with constant total receptors. By initial simulations, reasonable initial estimates could be determined for *V*, $R_{A}^{0}$, $R_{B}^{0}$ and partially for *k* ~el~ from *C* profiles, and initial estimates for *K* ~*D1*~, *K* ~*D2*~ from *R* ~A~, *R* ~B~ profiles. Effect of *k* ~int~ was visible in all three profiles. However, α was difficult to obtain from data by visual inspection also due to correlation with *K* ~*D1*~, *K* ~*D2*~. Fitting of *C* only, resulted in reasonable estimates for *V*, $R_{A}^{0},\, R_{B}^{0}$, *k* ~el~, *k* ~int~. However, *K* ~*D1*~, *K* ~*D2*~ needed to be fixed and were not estimable reflected by convergence problems. Inclusion of *R* ~A~, *R* ~B~ data to fitting, resulted in good final estimates for *V*, $R_{A}^{0},\, R_{B}^{0}$, *k* ~el~, *k* ~int~ and, in addition, *K* ~*D1*~, *K* ~*D2*~, whereas α was partially difficult to estimate and was, therefore, fixed. All parameters (true values, and initial and final estimates) are presented in **Table** [**2**](#psp412369-tbl-0002){ref-type="table"}. Applied source codes for MONOLIX and NONMEM, and visual predictive checks are available in **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}. We observed that sometimes representation Eqs. 15, 17, 25--30 caused convergence issues in MONOLIX and, therefore, we suggest using the representation Eqs. 15--23.

Effects of varying binding parameters and total receptor concentration on the TC {#psp412369-sec-0016}
--------------------------------------------------------------------------------

TC behavior with respect to total BsAb concentration and total receptor concentrations can be simulated for different binding parameters with the EB model *Eqs* 20--22 and 26--30. In **Figure** [**2**](#psp412369-fig-0002){ref-type="fig"} **b--e** the effect of varying *K* ~*D1*~, *K* ~*D2*~, $R_{totA}^{0},R_{totB}^{0}$, α are shown. The model predicted a decrease in TC concentration, even at significantly higher BsAb concentrations, with lower target affinities (*K* ~*D1*~, *K* ~*D2*~). Additionally, increase in α also reduced TC concentrations due to increase in dissociation constants. MATLAB code is available to test the effect of different model parameters in **Supplementary Material** [**\[Link\]**](#psp412369-sup-0001){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0002){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0003){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0004){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0005){ref-type="supplementary-material"} **--** [**\[Link\]**](#psp412369-sup-0006){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0007){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0008){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0009){ref-type="supplementary-material"}, [**\[Link\]**](#psp412369-sup-0010){ref-type="supplementary-material"}.

Optimal dosing strategy for maximal TC concentration {#psp412369-sec-0017}
----------------------------------------------------

First, the QE approximation with constant total receptors, realized with *k* ~int~ = *k* ~intA~ = *k* ~intB~ = *k* ~intAB~ = 0.1 is considered. Further we assume *k* ~el~ = *k* ~int~, allowing an explicit computation of the optimal dosing timepoints. For simplicity, the peripheral compartment was neglected. The constant total receptors $R_{totA}^{0} \equiv 10\;\text{nM}$, $R_{totB}^{0} \equiv 100\;\text{nM}$ define the optimal working range $R_{totA}^{0} \leq C_{tot}{(t)} \leq R_{totB}^{0}$ (**Figure** [**5**](#psp412369-fig-0005){ref-type="fig"} **b**). Hence, the optimal initial dose to achieve *C* ~tot~(0) = 100 is dose~init~ = 44.8 mg, see Eq. [(39)](#psp412369-disp-0043){ref-type="disp-formula"}. All subsequent doses are dose~seq~ = 40.3 mg, see Eq. [(41)](#psp412369-disp-0045){ref-type="disp-formula"}. Optimal re‐dosing was *t* ~opt~ = 23 day, computed by Eq. [(40)](#psp412369-disp-0044){ref-type="disp-formula"}. Note that (i) *C*(0) ≈ 1 due to high affinity, and (ii) *C* is already far below LLOQ at *t* ~opt~ (**Figure** [**5**](#psp412369-fig-0005){ref-type="fig"} **a**). Hence, although nearly no free BsAb is available, the system still runs (**Figure** [**5**](#psp412369-fig-0005){ref-type="fig"} **c**). A re‐dose at the time *t *=* *7 day, when LLOQ was reached for free BsAb would lead to suboptimal TC concentration.

![Optimal dosing strategy for i.v. and s.c. administration is visualized. The first example (**a--c**) considers constant total receptors and an i.v. bolus administration. (**a**) Free bispecific antibody (BsAb) concentration is shown after administration of the optimal i.v. bolus dose to keep the total BsAb concentration in the optimal working range (**b**) resulting in the maximal possible concentration of the ternary complex (**c**). Example was produced with the quasi‐equilibrium approximation with constant total receptors. The second example (**d--f**) considers nonconstant total receptors and an s.c. administration simulated with the full model.](PSP4-8-177-g005){#psp412369-fig-0005}

Second, the full model is considered with peripheral compartment and s.c. administration. Here, no explicit formulas for optimal doses and timepoints can be presented. However, simulations show that an initial dose of dose~init~ = 100 mg was sufficient to bring the total drug concentration in the upper limit of the optimal working range (**Figure** [**5**](#psp412369-fig-0005){ref-type="fig"} **e**). The optimal re‐dose timepoint was *t* ~opt~ = 50 day with subsequent doses of dose~seq~ = 100 mg. Again, free BsAb was below the LLOQ after 25 days but the optimal re‐dose timepoint is two times later.

Discussion {#psp412369-sec-0018}
==========

We have presented a TMDD model, along with its QE approximation, for BsAbs that are designed to work by forming a TC between two different cell types. The model includes typical antibody and target properties, such as linear elimination, a peripheral compartment, target turnover, and degradation/internalization of the BCs and TC.

The aims were (i) to construct model approximations to reduce the number of parameters, (ii) to reveal model properties that are discernible only in those simplified formulations, (iii) to construct an optimal dosing strategy to immediately build‐up and maintain the maximal TC concentration, and (iv) to use the full model and the approximations to investigate the effects of the model parameters on the dynamics.

Under the assumption of high affinity of the BsAb to its targets and limited capacity of the targets, rapid binding is the basic assumption to construct a QE approximation with a reduced number of parameters. Further parameter reduction is possible when either one or both total receptor concentrations are constant over time. We observed that because only the ratio of the binding parameters is used in the QE approximations, the absolute values of the binding parameters with same ratio are important for how the full model moves toward the approximation. Finally, the EB model was constructed (i.e., a QE model without target turnover, and elimination and internalization rates), which characterizes the TC concentration with respect to total BsAb concentration and the total receptors. How to set up a quasi‐steady state approximation was not obvious because the principle of microscopic reversibility relies on the dissociation constants and not on the steady state constant. Although, a Michaelis‐Menten approximation can be obtained by assuming the typical temporary property of full receptor occupancy, it was not possible to further reduce the number of parameters. As a result of the rapid binding approximation via an infinitely fast process, the matrix notation reveals that the i.v. drug input function is multiplied with different model states and appears at different positions in the model equations. This property was already observed for approximations of less complex TMDD models (e.g., for competitive interaction of endogenous and exogenous antibodies).[17](#psp412369-bib-0017){ref-type="ref"}, [29](#psp412369-bib-0029){ref-type="ref"} Unfortunately, most internal i.v. administration mechanisms in PK/PD software are not flexible enough to handle this situation. Hence, we demonstrated how an i.v. administration has to be included by the user in the model code of the QE approximation.

A second focus was the design of an optimal dosing strategy for maximal TC concentration. For that, we exploited properties from the EB model with respect to total BsAb concentration‐TC relationship. This led to the construction of an optimal working range for BsAbs. In this range, the total BsAb concentration is within the minimum and the maximum of both total receptor concentrations, leading to maximal possible TC concentration. By construction of the EB model, those results can be translated back to the QE approximation and finally under the rapid binding assumption to the full model. Please note that an optimal dosing strategy for patients has to account for intersubject variability in target turnover.

BsAbs are promising candidates for cancer immunotherapy. However, due to the cross‐linking structure of the formed complexes, the functional TC of BsAb shows different PK properties compared to classical concentration‐effect terms. More precisely, the model predicts a delayed build‐up of TC concentration for increasing doses. We have even showed that TC concentration tends to be zero for very high BsAb concentrations. This finding is corroborated by *in vitro* studies, performed by coculturing Jurkat T cells and Daudi B cells in the presence of CD19xCD3 DART, where a decrease in TC concentration was observed at higher concentrations of BsAb.[30](#psp412369-bib-0030){ref-type="ref"} For the development of an efficacious BsAb, a fine balance is required between target kinetics and antibody properties. The presented model was used to analyze the effects of various target and antibody related parameters on the formation of the TC. Due to the cross‐linking nature of the binding kinetics, we observed that although the free BsAb concentration can be below the LLOQ, the BsAb mechanism still produces maximal TC concentrations. Using the optimal working range, we showed how optimal re‐dosing timepoints and doses can be obtained. Another interesting aspect observed during the analysis was increase in target mediated clearance due to faster internalization of receptor. BsAb exhibit two inflection points in the concentration‐time curve, the first point is primarily due to elimination of BC and the second inflection indicates elimination of TC. Faster internalization of target receptors affects the first inflection point leading to faster elimination of BsAb. This inevitably shortens the residence time of BC and TC in the system (**Supplementary Material S1--S10**). Similarly, higher internalization of TC leads to faster elimination of BsAb, evident at the second inflection point (**Supplementary Material S1--S10**). Apart from providing insights into the key target‐related parameters that might affect the formation of TC, this model can also aid in predicting PKs of BsAb eliminating at different rates. Currently, there are different BsAb (i.e., full size immunoglobulin G BsAb and (ScFv)~2~ BsAb), which exhibit clearance in the range of 10^−5^ to 10^−3^ L/hour depending on their size and structure, and this model can provide a quantitative framework for suitable antibody selection and engineering.

In the future, the model and its approximation can be extended with (i) TC effects on target cells,[28](#psp412369-bib-0028){ref-type="ref"} (ii) T cell rebound phenomena,[31](#psp412369-bib-0031){ref-type="ref"} and (iii) integration of local geometrical structures on the cell surface for the cross‐linking binding reactions.[12](#psp412369-bib-0012){ref-type="ref"}, [13](#psp412369-bib-0013){ref-type="ref"} Inclusion of geometrical structures leads to mathematical models of the form Eqs. 1−8, with binding rates partially depending on the target concentrations. Development of a QE approximation and the design of an optimal dosing strategy for these kinds of models are interesting topics for future research.
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**Supplementary Material S1.** Supplemental material for target‐mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy.

###### 

Click here for additional data file.
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**Supplementary Material S2.** Matlab implementation of the model Eqs. [(20)](#psp412369-disp-0021){ref-type="disp-formula"}, [(21)](#psp412369-disp-0022){ref-type="disp-formula"}, [(22)](#psp412369-disp-0023){ref-type="disp-formula"} and [(26)](#psp412369-disp-0028){ref-type="disp-formula"}, [(27)](#psp412369-disp-0029){ref-type="disp-formula"}, [(28)](#psp412369-disp-0030){ref-type="disp-formula"}, [(29)](#psp412369-disp-0031){ref-type="disp-formula"}, [(30)](#psp412369-disp-0032){ref-type="disp-formula"}.
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Click here for additional data file.
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**Supplementary Material S3.** Example code of the quasi‐equilibrium approximation with nonconstant total receptors in MONOLIX.
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Click here for additional data file.
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**Supplementary Material S4.** Example code of the full model in MONOLIX.

###### 

Click here for additional data file.

###### 

**Supplementary Material S5.** Example code of the quasi‐equilibrium approximation with nonconstant total receptors in NONMEM.

###### 

Click here for additional data file.

###### 

**Supplementary Material S6.** Example code of the full model in NONMEM.

###### 

Click here for additional data file.

###### 

**Supplementary Material S7.** Applied MONOLIX source code for Eqs. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(16)](#psp412369-disp-0017){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, [(18)](#psp412369-disp-0019){ref-type="disp-formula"}, [(19)](#psp412369-disp-0020){ref-type="disp-formula"}, [(20)](#psp412369-disp-0021){ref-type="disp-formula"}, [(21)](#psp412369-disp-0022){ref-type="disp-formula"}, [(22)](#psp412369-disp-0023){ref-type="disp-formula"}, [(23)](#psp412369-disp-0025){ref-type="disp-formula"}.
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Click here for additional data file.
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**Supplementary Material S8.** Alternative MONOLIX source code for Eqs. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, and [(25)](#psp412369-disp-0027){ref-type="disp-formula"}, [(26)](#psp412369-disp-0028){ref-type="disp-formula"}, [(27)](#psp412369-disp-0029){ref-type="disp-formula"}, [(28)](#psp412369-disp-0030){ref-type="disp-formula"}, [(29)](#psp412369-disp-0031){ref-type="disp-formula"}, [(30)](#psp412369-disp-0032){ref-type="disp-formula"}.
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Click here for additional data file.

###### 

**Supplementary Material S9.** Applied NONMEM source code for Eqs. [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(16)](#psp412369-disp-0017){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, [(18)](#psp412369-disp-0019){ref-type="disp-formula"}, [(19)](#psp412369-disp-0020){ref-type="disp-formula"}, [(20)](#psp412369-disp-0021){ref-type="disp-formula"}, [(21)](#psp412369-disp-0022){ref-type="disp-formula"}, [(22)](#psp412369-disp-0023){ref-type="disp-formula"}, [(23)](#psp412369-disp-0025){ref-type="disp-formula"}.

###### 

Click here for additional data file.

###### 

**Supplementary Material S10.** Alternative NONMEM source code for Eqs.  [(15)](#psp412369-disp-0016){ref-type="disp-formula"}, [(17)](#psp412369-disp-0018){ref-type="disp-formula"}, and [(25)](#psp412369-disp-0027){ref-type="disp-formula"}, [(26)](#psp412369-disp-0028){ref-type="disp-formula"}, [(27)](#psp412369-disp-0029){ref-type="disp-formula"}, [(28)](#psp412369-disp-0030){ref-type="disp-formula"}, [(29)](#psp412369-disp-0031){ref-type="disp-formula"}, [(30)](#psp412369-disp-0032){ref-type="disp-formula"}.

###### 

Click here for additional data file.
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